Details
Category: Volume 07 Issue 05 May 2019
Hits: 1063

Title: Assessment of Inflammatory Markers among COPD Patients and Healthy Smokers

Authors: Eman Omar Arram, Noha Tharwat Abou El-Khier, Safaa Mohamad EL-Ageery

 DOI: https://dx.doi.org/10.18535/jmscr/v7i5.40

Abstract

Background: The pathogenesis of COPD patients includes a variety of systemic inflammatory factors in response to environmental stimuli particularly among cigarette smokers.

Aim of the work: This study aimed to show the levels of serum inflammatory markers as interleukin (IL-8),Tumor necrosis factor- alpha(TNF-α) and C-reactive protein (CRP)in stable Chronic obstructive pulmonary disease (COPD) patients, both healthy current  smokers and non-smokers, and to show its relation with smoking load and the severity of airway obstruction.

Patients and Methods: The study was conducted on 70 cases divided into three groups; 40 COPD patients, 20 healthy current smokers and 10 healthy non smokers as a control., All cases age and sex characteristics were similar, complete history taking, general, local chest examination, pulmonary function tests (PFT), Serum levels of interleukin (IL-8), tumor necrosis factor-alpha (TNF-α) and C-reactive protein (CRP) were measured in all groups.

Results: There were highly statistically significant difference (<0.001) as regards inflammatory cytokines IL8 and TNF-α and CRP among the three groups also as regard spirometer parameters. There were highly significant negative correlation between all markers and FEV1, while there were highly significant positive correlation between all markers and smoking load in COPD patients. There were highly significant negative correlation between all markers and FEV1 while significant positive correlation between only IL8 and pack-year index in healthy smoker group.

Conclusion: Plasma levels of inflammatory markers: IL8, TNF-α and CRP were high in COPD patients also the increase in serum inflammatory markers has a direct correlation with the severity of COPD and airway obstruction which conclude that markers of systemic inflammation have an important role in COPD pathogenesis.

Abbreviation: Chronic obstructive pulmonary disease (COPD),C-reactive protein (CRP),interleukin (IL-8), tumor necrosis factor-α (TNF-alpha), enzyme immunoassay (EIA), Forced expiratory volume in 1 second (FEV1).

Keywords: COPD, FEV1, IL8, TNF-α, CRP.

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Guidelines: Workshop report. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
  2. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J RespirCrit Care Med. 2002; 166: 1218–1224.
  3. Connors AF Jr., Dawson NV, Thomas C, Harrell FE Jr., Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J RespirCrit Care Med. 1996; 154: 959–967.
  4. Agustí A: Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am ThoracSoc 2007, 4:522-525.
  5. Foschino Barbaro MP, Carpagnano GE, Spanevello A, Cagnazzo MG, Barnes PJ. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol. 2007; 20: 753–763.
  6. Hacker S, Lambers C, Hoetzenecker K, Pollreisz A, Aigner C, Lichtenauer M, et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab. 2009; 55: 31–40.
  7. Turato G, Zuin R, Miniati M, et al. Airway inflammation insevere chronic obstructive pulmonary disease: relationshipwith lung function and radiologic emphysema. Am J RespirCrit Care Med 2002; 166: 105–110.
  8. Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronicbronchitis: inverse relationship of CD8zT lymphocytes withFEV1. Am J Respir Crit Care Med 1997; 155: 852–857.
  9. Akublut HH, Ozden M, Deveci F, Muz MH. IL-6 and IL-8 Levels in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. J ClinDiag Res 2009;3;1285-1288.
  10. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 18 :50-59.
  11. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNF-alpha in pulmonary pathophysiology. Respir Res 2006; 7 :125.
  12. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364: 709–721.
  13. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–2653.
  14. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflamma-tion in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519.
  15. Mehrotra N, Freire AX, Bauer DC, et al. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol 2010; 20: 223–232.
  16. Standardization of spirometry, 1994 update .Am J RespirCrit Care Med 1995;152:1107-1136.
  17. Bailey KL, Goraya J, Rennard SL. The role of systemic ýnflammation in COPD. Respir Med 2012; 2 :15-30.
  18. Hacievliyagil SS, Gunen H, Mutlu LC, et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006; 100 :846-854.
  19. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, MaestrelliP, Cavallesco G, Papi A, Fabbri LM: Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000, 161:1016-1021.
  20. Rutgers SR, Timens W, Kauffman HF, Postma DS: Markers of active airway inflammation and remodelling in chronic obstructive pulmonary disease. Clin Exp Allergy 2001, 31:193-205.
  21. Clapp BR, Hingorani AD, Kharbanda RK, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004;64:172–178.
  22. Aaron SD, Vandemheen KL, Ramsay T, Zhang C, Avnur Z, Nikolcheva T, et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res. 2010; 11: 41 10.1186/1465-9921-11-41
  23. Daldegan MB, Teixeira MM, Talvani A. Concentration of CCL11, CXCL8 and TNF-alpha in sputum and plasma of patients undergoing asthma or chronic obstructive pulmonary disease exacerbation. Braz J Med Biol Res 2005; 38 :1359-1365.
  24. Garcia-Rio F, Miravitlles M, Soriano J, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11-63.
  25. Demirci N, Atasever M, Ertürk H, et al. Correlation between high-resolution computed tomography, neutrophili-cýnflammation, air-way obstruction and serum ýnterleukin-8 levels in chronic obstructive pulmonary disease. J Clin Anal Med 2013; 4 :286-290.
  26. Churg A, Wang RD, Tai H, et al. Tumour necrosis factor-alpha drives 70% ofcigarette smoke-induced emphysema in the mouse. Am J RespirCrit Care Med2004;170:492-8.
  27. Takabatake N, Nakamura H, Abe S, Hino T, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J RespirCrit Care Med 1999; 159 :1215-1219.
  28. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J RespirCrit Care Med 2004; 170 :1286-1293.
  29. Abd El-Maksoud MD, Samy N, EL Khayyal A. Clinical utility of biomarkers as predictors of lung function in chronic obstructive pulmonary disease. N Y Sci J 2010; 3 :25-32.
  30. Garcia-Rio F, Miravitlles M, Soriano J, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11-63.
  31. Xie J, Yang X, Shi J, Deng X, et al. A new inflammation marker of chronic obstru-ctive pulmonary disease-adiponectin. World J Emerg Med 2010; 1 :190-195.
  32. Ibrahim EE, Zidan MH. The relation between the ýnflammatory mediators, quality of life, and classification of the gold guidelines of COPD patients. Egypt J Chest 2011; 60 :117-125.
  33. Abd El Aziz AA, Hammoudah MA, Farid W. Tumor-necrosis factor (TNF) alpha and pulmonary hypertension in patients with COPD. Egypt J Chest 2011; 60 :135-138.
  34. Bruno A, Alessi M, Soresi S, et al. Increased leptin/leptin receptor pathway affects systemic and airway inflammation in COPD former smokers. J Inflamm Res 2011; 4 :51-59.
  35. Van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GJ, Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc. 2006; 38: 1543–1552.
  36. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008; 19: 104–108.
  37. Petersen AM, Mittendorfer B, Magkos F, Iversen M, Pedersen BK. Physical activity counteracts increased whole-body protein breakdown in chronic obstructive pulmonary disease patients. Scand J Med Sci Sports. 2008; 18: 557–564.
  38. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7: e37483.
  39. Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008; 63: 100–107.
  40. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006; 61 :10-16.
  41. Amer MS, Wahba HM, Ashmawi SA, et al. Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease. Lung India 2010; 27 :225-229.
  42. Kanazawa H, Kurihara N, Otsuka T, et al. Clinical significance of serum concentration of interleukin 8 in patients with bronchial asthma or chronic pulmonary emphysema. Respiration 1996; 63 :236-240.
  43. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14 :1015-1022.
  44. Zhang J, Wu L, Qu J, Bai C, et al. Pro-inflammatory phenotype of COPD fibroblasts not compatible with repair in COPD lung. J Cell Mol Med 2011; 16 :1522-1532.
  45. Bathoorn E, Liesker JW, Postma DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis 2009; 4 :101-109.
  46. Akublut HH, Ozden M, Deveci F, Muz MH. IL-6 and IL-8 Levels in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. J ClinDiag Res 2009;3;1285-1288.
  47. Pinto-Plata VM, Livnat G, Girish M. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007; 131 :37-43.
  48. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–1812.
  49. Torres-Ramos YD, Garcia-Guillen ML, Olivares-Corichi IM, Hicks JJ. Correlation of plasma protein carbonyls and C-reactive protein with GOLD stage progression in COPD patients. Open Respir Med J. 2009;3:61–66.
  50. Aaron SD, Vandemheen KL, Ramsay T, Zhang C, Avnur Z, Nikolcheva T, et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res. 2010; 11: 41 10.1186/1465-9921-11-41.
  51. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. ThrombHaemost. 2009; 102: 1176–1182.
  52. Fattouh M, Alkady O. Inflammatory biomarkers in chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis. 2014; 63: 799–804.
  53. Harting JR, Gleason A, Romberger DJ, Von Essen SG, Qiu F, Alexis N, et al. Chronic obstructive pulmonary disease patients have greater systemic responsiveness to ex vivo stimulation with swine dust extract and its components versus healthy volunteers. J Toxicol Environ Health A. 2012; 75: 1456–1470.

Corresponding Author

Eman Omar Arram

Thoracic Medicine Department,

Faculty of Medicine, Mansoura University